Partners Group to Acquire Majority Stake in FairJourney Biologics

Partners Group has announced that it will acquire a majority stake in FairJourney Biologics, a leading antibody discovery Contract Research Organization (CRO) based in Porto, Portugal. The acquisition will be carried out on behalf of Partners Group’s clients, with GHO Capital Partners reinvesting in a minority stake.

FairJourney, founded in 2012, has established itself as a key player in the pharmaceutical and biotech sectors, providing services such as the discovery, engineering, production, and characterization of antibodies. The company has collaborated with over 250 clients globally and has contributed to the development of over 4,000 unique screening libraries and 14 active clinical therapies.

The acquisition by Partners Group aims to leverage the growing market for antibody discovery, driven by higher R&D spending and increased outsourcing. Partners Group will implement a value creation plan to expand FairJourney's technology and capabilities, supporting faster and more effective drug development.

Key figures such as António Parada, Founder and CEO of FairJourney, and Pascal Noth from Partners Group, have expressed optimism about the future growth and innovation potential unlocked by this partnership.